Edimer Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Edimer Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 11 completed early-phase tilt top decile by trial count

Edimer Pharmaceuticals: 11 sponsored US clinical trials, none currently recruiting.

Edimer Pharmaceuticals sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypohidrotic Ectodermal Dysplasia, with 1 trials.

Top-decile sponsor footprint

Edimer Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

11 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

11 total, page 1 of 1

COMPLETED

Natural History and Outcomes in X-Linked Hypohidrotic Ectodermal Dysplasia

NCT02099552
COMPLETED

Phenotypic Properties in Individuals Affected With XLHED

NCT01871714
COMPLETED Phase 2

Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)

NCT01775462
COMPLETED

Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status

NCT01629940
COMPLETED Phase 1

A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200

NCT01564225
COMPLETED

X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey

NCT01398813
COMPLETED

Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia: Intrafamilial Variation

NCT01386775
COMPLETED

Sweat Duct Imaging in Mother/Newborn Dyads

NCT01342133
COMPLETED

Medical Record Review of Hypohidrotic Ectodermal Dysplasia Clinical Phenotype

NCT01398397
COMPLETED

Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected by Hypohidrotic Ectodermal Dysplasia - A

NCT01293565
COMPLETED

Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia

NCT01108770

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Therapeutic Areas

Hypohidrotic Ectodermal Dysplasia 1
X-Linked Hypohidrotic Ectodermal Dysplasia 1

How the Edimer Pharmaceuticals early-phase archive is shaped

11 indexed studies, none listed as recruiting (0% open); 11 completed (100%).

Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).

Top condition: Hypohidrotic Ectodermal Dysplasia (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Edimer Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Edimer Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Edimer PharmaceuticalsAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiome10xBio22nd Century Group23andMe3-C Institute for Social Development
Edimer Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Edimer Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Edimer Pharmaceuticals page

11 registered trials is a research-attention snapshot, not an endorsement of Edimer Pharmaceuticals or any single study.

  • None of Edimer Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Hypohidrotic Ectodermal Dysplasia is the condition Edimer Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypohidrotic Ectodermal Dysplasia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Edimer Pharmaceuticals pipeline card: 11 registered trials from official public datasets.Report a data error.